Clinical Management

AG10 has the potential to be clinically efficacious in patients with a variety of genotypes associated with both TTR cardiomyopathy and polyneuropathy. Read More ›


The ANDROMEDA study revealed a significant hematologic complete response rate in patients with newly diagnosed light chain amyloidosis treated with daratumumab plus hyaluronidase human-fihj. Read More ›

The presence of severe aortic stenosis in the context of transthyretin cardiac amyloidosis is associated with a dramatic reduction in patient survival. Read More ›

Increasing awareness of Amyloidosis Programs’ best practices may help inform healthcare providers of the benefits of early referral and multidisciplinary comprehensive patient care. Read More ›

In a select group of patients with transthyretin cardiac amyloidosis (TTR-CA) and heart failure with reduced ejection fraction, guideline-directed medical therapy may be beneficial. Read More ›

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.

I'd like to receive: